Boehringer partners on fibrosing lung disease research

German family-owned pharma major pharmaceutical company Boehringer Ingelheim has entered partnership with AI company Brainomix for a collaborative program of activity to improve the care of patients with fibrosing lung disease in the USA.

The project will focus on the opportunity for AI imaging analysis using Brainomix 360 e-Lung on routine CT scans to accelerate the diagnosis and improve access to treatment for people living with fibrosing lung disease.

Through this partnership, Brainomix will deploy its Food and Drug Administration (FDA)-cleared e-Lung software to leading US pulmonology centers and their networks of referring sites. The data generated will validate the value of e-Lung, highlighting the potential of digital technology to optimize pathways of care and improve outcomes for people with fibrosing lung disease, a vision shared between Brainomix and Boehringer Ingelheim.